ArticleData in brief2026
Data on microRNA transcriptomic signatures, predicted gene targets and pathway analysis in response to cetuximab or panitumumab in colorectal cancer cells.
Article in Data in brief, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Resistance to anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (mAb) is common in metastatic colorectal cancer (mCRC) and reliable predictive biomarkers remain lacking. The identification of new predictive biomarkers is therefore necessary to assess the efficacy of anti-EGFR mAb, in order to optimize the therapeutic strategy for mCRC. Micro-RNAs (miR) are small non-coding RNAs that primarily regulate gene expression, and whose dysregulation in anti-EGFR resistance has been widely reported in CRC. Following a previous analysis using a miRnome strategy, the present study focused on NGS (next-generation sequencing) to investigate a broader range of miRNAs. We identified several miR resistance signatures as well as potential target genes and associated pathways following exposure to different doses of cetuximab or panitumumab in colorectal cancer cells. In the context of the search for useful biomarkers for this cancer, this could help optimize the design of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.